

**ARGENT BIOPHARMA LTD  
AND CONTROLLED ENTITIES  
ABN 30 116 800 269**

**APPENDIX 4D**

**REPORTING PERIOD**

Interim financial period to 31 December 2025

**PREVIOUS REPORTING PERIOD**

Interim financial period to 31 December 2024

**Half year information given to ASX under listing rule 4.2A.3**

This information contained in this report should be read in conjunction with the most recent annual report.

	31-Dec-25	30-Jun-25
<b>NET TANGIBLE ASSETS PER ORDINARY SHARE (cents)</b>	(0.1)	(0.1)

**RESULTS FOR ANNOUNCEMENT TO MARKET**

	31-Dec-25 \$	Change %	31-Dec-24 \$
Revenue from ordinary activities	171,499	3,904% increase	4,283
Loss after income tax from ordinary activities attributable to members	(2,935,261)	76% decrease	(12,161,780)
Net loss for the period attributable to members	(2,935,261)	76% decrease	(12,161,780)
Dividend per share	n/a		n/a
Record date for determining entitlement to dividends	n/a		n/a
No dividends have been paid or declared during the year			

**DETAILS OF SUBSIDIARIES**

During the period, there were no newly incorporated nor newly acquired entities.

In December 2025, the Group lost control of its Slovenian subsidiary, Argent BioPharma d.o.o., following a strategic decision to liquidate the entity. This resulted in a statutory loss on liquidation of \$55,395 recognised during the period. Further details are provided in Note 12 of the half-year financial report.

<b>DIVIDENDS</b>	n/a	n/a
<b>DIVIDENDS REINVESTMENT PLAN</b>	n/a	n/a
<b>ASSOCIATED AND JOINT VENTURE ENTITIES</b>	n/a	n/a

**FOREIGN ENTITIES ACCOUNTING STANDARD**

*Subsidiaries are incorporated in the United Kingdom, Slovenia and Malta, where International Financial Reporting Standards are applied.*

**AUDIT DISPUTE OR QUALIFICATION**

*Not subject to a modified opinion, however an emphasis of matter paragraph has been included in the independent auditor's review report in relation to the Group's going concern assessment (refer to note 2 of the interim financial report).*



ABN 30 116 800 269  
ARGENT BIOPHARMA LTD

## INTERIM FINANCIAL REPORT

31 DECEMBER 2025

For personal use only

**Contents**

**Corporate Directory** ..... 4

**Directors’ Report**..... 5

**Auditor’s Independence Declaration** ..... 8

**Consolidated Statement of Profit or Loss and Other Comprehensive Income**..... 9

**Consolidated Statement of Financial Position** ..... 10

**Consolidated Statement of Changes in Equity**..... 11

**Consolidated Statement of Cash Flows**..... 12

**Notes to the Consolidated Interim Financial Statements** ..... 13

**Directors’ Declaration** ..... 20

**Independent Review Report to Members** ..... 21

For personal use only

## Corporate Directory

### Directors

**Roby Zomer** Managing Director and CEO  
**Gary Hermon** Non-Executive Director  
**Daniel Robinson** Non-Executive Director

### Company Secretary

Rowan Harland

### Registered Office and Principal Place of Business

Suite 1, 295 Rokeby Road  
Subiaco WA 6008  
Tel: +61 8 6555 2950

### Solicitors

Steinepreis Paganin  
Level 4, The Read Buildings  
16 Milligan Street  
Perth WA 6000

### Auditors

Hall Chadwick  
Level 40, 2 Park Street  
Sydney NSW 2000

### Securities Exchange Listing

Argent BioPharma Ltd securities are listed on the Australian Securities Exchange (ASX) and the OTC Markets, QB Tier.  
ASX Code: RGT  
OTCQB Code: RGTLF

### Share Registry

Computershare Investor Services Pty Limited  
Level 17  
221 St Georges Terrace  
Perth WA 6000

### Website

[www.argentbiopharma.com](http://www.argentbiopharma.com)

For personal use only

## Directors' Report

The directors submit the consolidated interim financial report for Argent BioPharma and its controlled entities (the "Group" or "Argent BioPharma") for the half-year ended 31 December 2025.

### Directors

The names of directors who held office during or since the end of the half-year, all still currently hold office:

Director	Title	Appointment Date	Resignation Date
Roby Zomer	Managing Director & CEO	15 February 2016	-
Gary Hermon	Non-Executive Director	5 March 2025	-
Daniel Robinson	Non-Executive Director	1 December 2023	-
Layton Mills	Non-Executive Director	1 June 2023	5 March 2025

### Operating Results

The consolidated operating losses for the Group after providing for income tax from continuing operations amounted to A\$2.9m (31 Dec 2024: A\$12.2m).

### Dividends Paid or Recommended

No dividends have been paid or declared for payment during the financial period.

### Review of Operations

#### Half Year Highlights:

#### Binding agreement signed for strategic acquisition of AusCann assets to advance CannEpiI

Subsequent to the period, Argent restructured the asset transaction with AusCann Group Holdings Ltd which was previously announced in August. The restructure was designed to streamline and strengthen the Company's clinical pipeline, intellectual property position and early commercialisation pathways. The revised transaction included the acquisition of AusCann's 48% equity interest in CannPal Animal Therapeutics Pty Ltd and an option to secure full ownership of the Neuvis<sup>®</sup> drug-delivery platform intellectual property, enhancing lifecycle development opportunities across key programs including CannEpiI<sup>®</sup> and CimetrA<sup>®</sup>. The transaction supports Argent's strategic focus on advancing its core drug assets through incorporation of validated preclinical data and regulatory pathway enhancements. Completion is subject to shareholder approval, with finalisation expected in early Q2 2026.

#### Independent U.S. In Vivo Study Demonstrates ArtemiC™ Efficacy in Viral Inflammatory Model

Positive results were received from an independent in vivo study conducted by the University of South Florida (USF), showing up to 85% survival in treated mice versus 0% in the control group within a severe viral inflammatory model. The study, independently funded by AMC Pharma USA, confirmed that ArtemiC™ (the U.S. OTC brand name of CimetrA<sup>®</sup>) significantly reduced viral load and cytokine-driven inflammation in lung and brain tissue, supporting its mechanism as a nano-formulated immunomodulator without immunosuppressive effects.

Completed in April 2025 and published in August 2025, the study provides strong scientific validation for AMC Pharma's U.S. commercial strategy and supports ongoing engagement with U.S. health policy stakeholders. ArtemiC™, Argent's lead nano-formulated oral therapy for Acute Respiratory Distress Syndrome (ARDS) and related inflammatory conditions, continues to demonstrate a strong safety profile and consistent therapeutic benefit across multiple preclinical and clinical programs.

### Supply of EU-GMP Cannabinoid API for Epilepsy Treatment at Leading EU Hospital

The Company commenced formal supply of EU-GMP cannabinoid-based active pharmaceutical ingredient (API) to the University Medical Centre Ljubljana (UKC). Transitioning from a structured pilot to routine hospital use, the RGT supply of this cannabinoid-based API enables neurologists to dispense recommended, protocol-aligned formulations for patients with drug-resistant epilepsy. This represented a significant new clinical milestone for the Company and has opened new potential commercial opportunities for API supply to EU hospitals.

This milestone was the culmination of a multi-year collaboration between Argent and the Slovenian University Medical Centre. The Company's pre-clinical data, GMP dossiers and clinical experience with CannEpi<sup>®</sup> now govern hospital-based compounding of cannabinoid therapies for neurological indications. The API is produced by PHCANN International/NYSK Holdings, one of Argent's EU-GMP Manufacturing partners.

### Peer-Reviewed Case Study for CannEpi<sup>®</sup> in Treatment-Resistant Epilepsy

During the period, a new independent, peer-reviewed case study was published in the International Journal of Clinical Medicine & Case Reports, highlighting the therapeutic potential of CannEpi<sup>®</sup> in managing treatment-resistant epilepsy.

The article, titled "Management of Lennox-Gastaut Syndrome with a CBD/THC Isolate Combination" (DOI: 10.46998/IJCMCR.2025.54.001331), details the successful treatment of a pediatric patient with Lennox-Gastaut Syndrome using CannEpi<sup>®</sup>, a proprietary CBD/THC isolate formulation produced under EU-GMP standards by Argent BioPharma.

The case study, authored by Argent's VP of Medical Development Dr. Jonathan Grunfeld and Medical researcher Dr. Jasna Jarc, describes a dramatic improvement in seizure control, cognitive ability, and overall quality of life. Notably, the patient experienced:

- Reduced seizure clusters and daily seizure frequency
- Recovery of speech, fine motor control, and independent mobility
- Reintegration into a full-time educational environment

This publication strengthens the growing body of real-world evidence supporting CannEpi<sup>®</sup>'s use in complex epilepsy syndromes and underscores the benefit of using pharmaceutical-grade isolate combinations over full-spectrum botanical preparations—providing both dosing precision and enhanced safety.

### Funding

Throughout the period, Argent BioPharma secured funding from two investment funds managed by US-based C/M Capital Partners, LP and has entered into a new convertible securities financing agreement with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC, both United States-based institutional funds to provide the Company with a substantial funding facility of up to a total of A\$11,000,000. This included an immediate \$3,000,000 drawdown for working capital and to complete the AusCann asset acquisition.

C/M Capital have been a long-term financier and key supporter of Argent since 2020 and are very pleased to continue their financial and advisory support to the Company. C/M Capital have deep rooted experience and expertise in investing in biotech and biopharma technology and development companies in the USA and on the ASX, including funding companies like Dimerix Limited (ASX: DXB).

**Events Subsequent to Reporting Date**

Refer to note 13 of the consolidated interim financial report for details of events that occurring after the reporting period.

**Auditor's Independence Declaration**

The lead auditor's independence declaration under section 307C of the Corporations Act 2001 is set out on the following page for the half-year ended 31 December 2025.

This report is signed in accordance with a resolution of the Board of Directors.

A handwritten signature in black ink that reads 'R. Zomer'.

Roby Zomer  
Managing Director & CEO  
Dated 27 February 2026

For personal use only

ARGENT BIOPHARMA LTD  
ABN 30 116 800 269  
AND ITS CONTROLLED ENTITIES

AUDITOR'S INDEPENDENCE DECLARATION  
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001  
TO THE DIRECTORS OF MGC PHARMACEUTICALS LTD

In accordance with Section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of Argent Biopharma Ltd. As the lead audit partner for the review of the financial report of Argent Biopharma Ltd for the half-year ended 31 December 2025, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- i. the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the review; and
- ii. any applicable code of professional conduct in relation to the review.



HALL CHADWICK (NSW)  
Level 40, 2 Park Street  
Sydney NSW 2000



**ANTHONY TRAVERS**

Partner

Dated: 27 February 2026

For personal use only

ADELAIDE	BRISBANE	DARWIN	MELBOURNE	PERTH	SYDNEY
Level 9	Level 4	Level 1	Level 14	Level 11	Level 40
50 Pirie Street	240 Queen Street	48-50 Smith Street	440 Collins Street	77 St Georges Tce	2 Park Street
Adelaide SA 5000	Brisbane QLD 4000	Darwin NT 0800	Melbourne VIC 3000	Perth WA 6000	Sydney NSW 2000
+61 8 7093 8283	+61 7 2111 7000	+61 8 8943 0645	+61 3 9820 6400	+61 8 6557 6200	+61 2 9263 2600

Liability limited by a scheme approved under Professional Standards Legislation. Hall Chadwick (NSW) Pty Ltd ABN: 32 103 221 352

[www.hallchadwick.com.au](http://www.hallchadwick.com.au)

## Consolidated Statement of Profit or Loss and Other Comprehensive Income For the half year ended 31 December 2025

		31-Dec-25 A\$	31-Dec-24 A\$
Revenue from contracts with customers	3	171,499	4,283
Cost of sales		(207,026)	(3,761)
<b>Gross profit</b>		<b>(35,527)</b>	<b>522</b>
Other operating income		-	348,968
Administrative expenses	10	(2,516,192)	(7,663,147)
Research and Development expenses		(402,303)	(630,173)
Other operating expenses		(26,101)	(822,974)
Reversal of (impairment expense)	5	-	(1,374,644)
<b>Operating loss</b>		<b>(2,980,123)</b>	<b>(10,141,448)</b>
Loss on liquidation of subsidiary	12	(55,395)	-
Finance costs		(33,506)	(31,180)
Finance income		-	2,243
Other expenses		-	(2,151,093)
Other income		133,763	159,698
<b>Loss before income tax</b>		<b>(2,935,261)</b>	<b>(12,161,780)</b>
Income tax expense		-	-
<b>Loss for the half-year</b>		<b>(2,935,261)</b>	<b>(12,161,780)</b>
Attributable to:			
Members of the parent entity		(2,935,261)	(12,161,780)
Non-controlling interest		-	-
		<b>(2,935,261)</b>	<b>(12,161,780)</b>
<b>Other comprehensive income</b>			
<b>Items that may be reclassified subsequently to profit or loss</b>			
Exchange differences on the translation of foreign operations		394,765	97,194
<b>Other comprehensive income (net of tax)</b>		<b>394,765</b>	<b>97,194</b>
<b>Total comprehensive loss</b>		<b>(2,540,496)</b>	<b>(12,064,586)</b>
<b>Total comprehensive loss attributable to:</b>			
Members of the parent entity		(2,540,496)	(12,064,586)
Non-controlling interest		-	-
		<b>(2,540,496)</b>	<b>(12,064,586)</b>
<b>Earnings per share</b>			
Basic loss for the half-year attributable to ordinary equity holders of the parent		(3.85)	(24.00)
Diluted loss for the half-year attributable to ordinary equity holders of the parent		(3.85)	(24.00)

The accompanying notes form part of these consolidated interim financial statements.

## Consolidated Statement of Financial Position

### As at 31 December 2025

	Note	31-Dec-25 A\$	30-Jun-25 A\$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents		1,529,444	1,024,405
Inventory		-	132,671
Trade and other receivables		237,225	375,648
Prepayments		124,254	496,890
<b>Total Current Assets</b>		<b>1,890,923</b>	<b>2,029,614</b>
<b>NON-CURRENT ASSETS</b>			
Plant and equipment	4	63,642	79,088
Investments accounted for using the equity method	5	-	-
Right-of-use assets	9	55,857	358,976
<b>Total Non-Current Assets</b>		<b>119,499</b>	<b>438,064</b>
<b>TOTAL ASSETS</b>		<b>2,010,422</b>	<b>2,467,678</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables		1,543,648	2,791,655
Financial liabilities at fair value through profit or loss	6	7,529,515	7,929,515
Lease liabilities	9	14,502	109,182
<b>Total Current Liabilities</b>		<b>9,087,665</b>	<b>10,830,352</b>
<b>NON-CURRENT LIABILITIES</b>			
Financial liabilities at fair value through profit or loss	6	1,312,219	-
Provision		-	18,706
Lease liabilities	9	55,251	248,545
<b>Total Non-Current Liabilities</b>		<b>1,367,470</b>	<b>267,251</b>
<b>TOTAL LIABILITIES</b>		<b>10,455,135</b>	<b>11,097,603</b>
<b>NET ASSETS</b>		<b>(8,444,713)</b>	<b>(8,629,925)</b>
<b>EQUITY</b>			
Contributed equity	7	139,618,424	138,587,034
Share based payment reserve	8	3,041,654	1,347,336
Foreign currency translation reserve		(656,812)	(1,051,577)
Accumulated losses		(150,447,979)	(147,512,718)
<b>Equity attributable to equity holders of the parent</b>		<b>(8,444,713)</b>	<b>(8,629,925)</b>
Non-controlling interest		-	-
<b>TOTAL EQUITY</b>		<b>(8,444,713)</b>	<b>(8,629,925)</b>

The accompanying notes form part of these consolidated interim financial statements.

For personal use only

## Consolidated Statement of Changes in Equity

## For the half year ended 31 December 2025

	Contributed Equity	Share Based Payment Reserve	Foreign Currency Translation Reserve	Accumulated losses	Non- controlling interest	Total
	A\$	A\$	A\$	A\$	A\$	A\$
<b>Balance at 1 July 2024</b>	<b>123,288,573</b>	<b>1,298,937</b>	<b>(71,535)</b>	<b>(129,668,423)</b>	<b>(672,372)</b>	<b>(5,824,820)</b>
Other comprehensive income	-	-	97,194	-	-	97,194
Loss after income tax expense	-	-	-	(12,161,780)	-	(12,161,780)
<b>Total comprehensive loss for the period</b>	<b>-</b>	<b>-</b>	<b>97,194</b>	<b>(12,161,780)</b>	<b>-</b>	<b>(12,064,586)</b>
Shares issued during the period (net of share issue costs)	5,986,911	-	-	-	-	5,986,911
Exercise of performance rights	116	(116)	-	-	-	-
Share based payments	-	48,515	-	-	-	48,515
Derecognition of MGC Pharmaceuticals (sro)	-	-	-	-	672,372	672,372
Conversion of convertible note	300,000	-	-	-	-	300,000
<b>Balance at 31 December 2024</b>	<b>129,575,600</b>	<b>1,347,336</b>	<b>25,659</b>	<b>(141,830,202)</b>	<b>-</b>	<b>(10,881,608)</b>
<b>Balance at 1 July 2025</b>	<b>138,587,034</b>	<b>1,347,336</b>	<b>(1,051,577)</b>	<b>(147,512,718)</b>	<b>-</b>	<b>(8,629,925)</b>
Other comprehensive income	-	-	394,765	-	-	394,765
Loss after income tax expense	-	-	-	(2,935,261)	-	(2,935,261)
<b>Total comprehensive loss for the period</b>	<b>-</b>	<b>-</b>	<b>394,765</b>	<b>(2,935,261)</b>	<b>-</b>	<b>(2,540,496)</b>
Shares issued during the period (net of share issue costs)	631,390	-	-	-	-	631,390
Options issued during the period	-	1,687,781	-	-	-	1,687,781
Share based payments	-	6,537	-	-	-	6,537
Conversion of convertible note	400,000	-	-	-	-	400,000
<b>Balance at 31 December 2025</b>	<b>139,618,424</b>	<b>3,041,654</b>	<b>(656,812)</b>	<b>(150,447,979)</b>	<b>-</b>	<b>(8,444,713)</b>

The accompanying notes form part of these consolidated interim financial statements.

## Consolidated Statement of Cash Flows For the half year ended 31 December 2025

	31-Dec-25 A\$	31-Dec-24 A\$
<b><i>Cash flows from operating activities</i></b>		
Receipts from customers	135,266	101,061
Payments to suppliers and employees	(2,582,105)	(3,840,069)
Payments for research expenses	(159,636)	(545,238)
Interest received	-	10,187
Interest paid	-	(571)
<b>Net cash used in operating activities</b>	<b>(2,606,475)</b>	<b>(4,274,630)</b>
<b><i>Cash flows from investing activities</i></b>		
Purchase of plant and equipment	(1,612)	(2,260)
Proceeds from disposal of plant and equipment	891	-
<b>Net cash used in investing activities</b>	<b>(721)</b>	<b>(2,260)</b>
<b><i>Cash flows from financing activities</i></b>		
Proceeds from issue of shares	-	4,623,912
Proceeds from shares not yet issued	271,978	-
Proceeds from convertible notes	3,000,000	-
Payment of lease liabilities	(123,446)	(135,461)
Payment of capital raising costs	(32,905)	(189,090)
<b>Net cash provided by financing activities</b>	<b>3,115,627</b>	<b>4,299,361</b>
<b>Net increase in cash and cash equivalents held</b>	<b>508,431</b>	<b>22,471</b>
Cash and cash equivalents at beginning of period	1,024,405	702,870
Foreign exchange movement of cash	(3,392)	(6,954)
<b>Cash and cash equivalents at end of period</b>	<b>1,529,444</b>	<b>718,387</b>

*The accompanying notes form part of these consolidated interim financial statements.*

## Notes to the Consolidated Interim Financial Statements

### NOTE 1. CORPORATE INFORMATION

The consolidated interim financial report of Argent BioPharma Ltd ('Argent BioPharma' or the 'Company') and its controlled entities (the "Group") for the half-year ended 31 December 2025 was authorised for issue in accordance with a resolution of the directors dated 27 February 2026.

Argent BioPharma Ltd is a Company limited by shares incorporated in Australia whose shares are publicly traded on the Australian Securities Exchange (primary market) and the OTCQB (secondary market).

### NOTE 2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

#### Statement of Compliance

The consolidated interim financial report is a condensed general purpose financial report prepared in accordance with the Corporations Act 2001 and AASB 134 'Interim Financial Reporting'. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'. The half-year report does not include notes of the type normally included in an annual financial report and should be read in conjunction with the annual financial report for the year ended 30 June 2025 and any public announcements made by the Group during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

#### Basis of Preparation

The consolidated interim financial statements have been prepared on the basis of historical cost, except for the revaluation of certain financial assets and liabilities. All amounts are presented in Australian dollars, unless otherwise noted.

The accounting policies and methods of computation adopted in the preparation of the consolidated interim financial report for the half-year ended 31 December 2025 are consistent with those adopted and disclosed in the Group's 2025 annual financial report for the financial year ended 30 June 2025.

#### Going Concern

At 31 December 2025, the Group had a cash and cash equivalents balance of A\$1,529,444 and had a net working capital deficit of A\$7,196,742, which included convertible notes with a face value of A\$7,529,515 which are currently under negotiation for change of conversion terms in order to improve the Group's working capital. The Group incurred a loss for the half year ended 31 December 2025 of A\$2,935,261 and had net cash outflows from operating and investing activities of A\$2,607,196.

The Group's cashflow forecasts for the 12 months from the date of this report indicate that the Group will require additional capital to meet its expenditure requirements and carry out its planned activities. Due to the ongoing capital raising activity and the continued support from the existing convertible note holder, the Directors are confident that additional capital can be raised as needed to meet current commitments and support further planned activities.

Based on the matters detailed above, the Directors are satisfied that the going concern basis of preparation is appropriate and that the Group will be able to realise its assets and settle its obligations in the ordinary course of business over the next 12 months.

The consolidated interim financial report has been prepared on a going concern basis which contemplates continuity of normal business activities and realisation of assets and settlement of liabilities in the normal course of business. In the event that the Group is unable to obtain additional funding, there is significant uncertainty as to whether the Group will be able to meet its debts as and when they fall due and thus continue as a going concern. The consolidated interim financial report does not include any adjustments relating to the recoverability and classification of the recorded asset amounts, nor to the amounts or classification of liabilities that might be necessary should the Group not be able to continue as a going concern.

### Comparative Figures

When required by Accounting Standards, comparative figures have been adjusted to conform changes in presentation for the current financial period.

#### a) New and amended Accounting Standards and Interpretations adopted by the Group

The Group has adopted all new and revised Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective from 1 July 2025.

The adoption of these new and amended Accounting Standards and Interpretations did not result in any significant changes to the Group's accounting policies.

The Group has not early adopted any new or amended Accounting Standards or Interpretations issued but not yet effective.

#### b) Significant Accounting Judgments, Estimates and Assumptions

In preparing these consolidated interim financial statements, significant judgements made by management in applying the Company's accounting policies and key sources of estimation uncertainty were the same as those that were applied to the consolidated financial statements as at and for the year ended 30 June 2025.

### NOTE 3. REVENUE

	31-Dec-25 A\$	31-Dec-24 A\$
<b>Revenue from contracts with customers</b>		
Pharma sales	166,181	-
Non-pharma sales	5,318	4,283
	<b>171,499</b>	<b>4,283</b>

### NOTE 4. PLANT AND EQUIPMENT

	31-Dec-25 A\$	30-Jun-25 A\$
<b>Plant and equipment</b>		
- gross carrying amount at cost	143,532	953,419
- accumulated depreciation	(79,890)	(874,331)
	<b>63,642</b>	<b>79,088</b>

<b>Plant and equipment movement</b>		
Opening balance at 1 July	79,088	5,661,603
Additions	1,612	2,231
Disposals	(26,266)	(335,001)
Impairment of PPE	-	(4,539,459)
Depreciation	(36,687)	(562,591)
Liquidation of subsidiary (Note 12)	(1,133)	-
Foreign exchange	47,028	(147,695)
	<b>63,642</b>	<b>79,088</b>

As part of Argent's ongoing optimization strategy for 2025, the Company has made a strategic decision to cease operations at two of its manufacturing facilities, located in Slovenia and Malta. This transition is aligned with our broader efforts to streamline resources, enhance efficiency, and focus on high-value areas such as research and development (R&D).

The decision to discontinue manufacturing activities at these sites has resulted in an impairment assessment of the related Property, Plant, and Equipment. Given that these assets will no longer be used for production and their recoverable amounts are lower than their carrying values, an impairment charge has been recognized in the financial statements in prior period.

Despite this transition, Argent remains committed to supporting patients using the Company's Investigational Medicinal Products (IMPs) under the special access scheme, ensuring continuity of care while further informing the development of our lead pharmaceutical candidates—the core focus of our business.

This strategic realignment allows Argent to reduce operational demands, allocate resources more efficiently, and drive innovation in pharmaceutical development, ultimately positioning the Company for sustainable long-term growth.

The net impairment charge after derecognition of the deferred revenue balance recognized in FY2025 was A\$980,431. No reversal of impairment has been recognized in December 2025.

#### **NOTE 5. IMPAIRMENT EXPENSE / INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD**

On 5 August 2022 the Company acquired 40% of the issued capital of ZAM Software Ltd, a private entity that owns a real-time data collection software with proprietary Artificial Intelligence (AI) algorithms.

During the current reporting period, the Company reassessed the carrying value of its 40% investment in ZAM Software Ltd. After recognizing a reversal of impairment in the previous year due to an independent valuation and successful capital raising, further analysis has been conducted to evaluate the investment's recoverable amount.

As a result, the Company has determined that an impairment indicator is present, leading to a full write-down of the investment's carrying value. In FY 2025, the Company has recognized an impairment charge of A\$1,408,140.

This impairment charge is reflected in the financial statements for the prior period, ensuring that the Company's financial position accurately represents the recoverability of its assets.

No reversal of impairment has been recognized in December 2025.

#### **NOTE 6. FINANCIAL INSTRUMENTS AT FAIR VALUE THROUGH PROFIT OR LOSS**

##### **Convertible notes**

##### **Australian Dollar (A\$) Denominated Facility**

In September 2020, the Company entered into a convertible note facility with Mercer Street Global Opportunity Fund (Mercer) for up to A\$15,000,000. Under this agreement, funds could be drawn in exchange for convertible notes with a face value of A\$1.00 each, equal to 110% of the amount received. The facility expired on 8 March 2022 and can no longer be accessed. Notes issued under this facility were repayable at face value 12 months from drawdown, unless converted or repurchased earlier.

On 1 February 2023, the Company executed an agreement to extend the maturity date of A\$2,100,000 in convertible notes to 1 February 2024 under the 2020 Extension Agreement. These notes remained convertible at Mercer's discretion at the lower of A\$35.00 or 92% of the lowest daily VWAP over a 10-day period, with a minimum conversion price of A\$10.00.

Additionally, in FY2024, the Company executed a Deed of Variation with Mercer to refinance 500,000 convertible notes from the 2020 facility, reducing the minimum conversion price from A\$10.00 to A\$0.35.

In FY2025, an agreement was reached with Mercer Street Capital Partners LLC to refinance an additional 300,000 notes from the 2020 Convertible Notes facility. This resulted in the minimum conversion price being amended from A\$10.00 to A\$0.30, after which the refinanced notes were converted into ordinary shares.

In September 2025, 400,000 notes were converted to 3,333,333 ordinary shares. This resulted in the minimum conversion price being amended to A\$0.12. In November 2025, the parties executed a Deed of Variation to amend the minimum conversion price to A\$0.04 and to extend the maturity date to 28 November 2026.

In November 2025, the Company entered into convertible securities agreements with C/M Capital Master Fund, LP and WVP Emerging Manager Onshore Fund LLC – C/M Capital Series. Under the agreements, the investors agreed to invest an aggregate amount of A\$3,000,000, with the potential to increase the total investment to an aggregate of A\$8,000,000 through further investments.

Under this agreement, funds could be drawn in exchange for convertible notes with a face value of A\$1.00 each, equal to 110% of the amount received. During the period, the Company received initial investments of A\$1,950,000 and A\$1,050,000 under the respective agreements.

In connection with the A\$3,000,000 of convertible notes issued during the period, the Company also issued 21,950,952 free-attaching options to the investors. The fair value of these options, amounting to A\$1,687,781, has been recognised directly in the Options Reserve in accordance with AASB 132. The residual proceeds of A\$1,312,219 have been recognised as a financial liability at fair value through profit or loss.

#### US Dollar (US\$) Denominated Facility

In July 2021, the Company entered into a US\$10,000,000 convertible note facility with Mercer, which is set to expire on 18 January 2024. Notes issued under this facility have a face value of US\$1.00 each and are repayable 18 months from drawdown, unless converted or repurchased earlier.

Between 19 July 2022 and 7 March 2023 (PY), the Company drew down US\$4,733,120 (A\$7,581,350) from this facility, issuing an equivalent number of convertible notes. These notes remain convertible at Mercer’s discretion at the lower of A\$20.00 or 90% of the lowest daily VWAP over a 10-day period, with a minimum conversion price of A\$10.00.

In November 2025, the parties executed a Deed of Variation to amend the minimum conversion price to A\$0.04 and to extend the maturity date to 28 November 2026.

The Company continues to explore further agreements with Mercer.

Both convertible notes are classified as hybrid financial instruments and are measured at fair value through profit or loss.

	31-Dec-25 A\$	30-Jun-25 A\$
<b>Financial liabilities at fair value through profit or loss</b>		
Opening balance	7,929,515	8,679,515
Additional borrowing	3,000,000	-
Fair value of options recognised in equity	(1,687,781)	-
Converted to ordinary shares	(400,000)	(550,000)
Repayment of borrowing	-	(200,000)
<b>Closing balance – fair value</b>	<b>8,841,734</b>	<b>7,929,515</b>
Current	7,529,515	7,929,515
Non-current	1,312,219	-
<b>Total Financial liabilities at fair value through profit or loss</b>	<b>8,841,734</b>	<b>7,929,515</b>

The fair value (Level 3) of the hybrid instruments was determined using valuation techniques including use of a Black-Scholes option pricing model, with estimates of projected conversion prices and the following significant inputs to the valuation at 31 December 2025. The directors have determined no fair value adjustment is necessary at the reporting date.

	Australian dollar facility	US dollar facility
Valuation date	31 December 2025	31 December 2025
Share price	\$0.07	\$0.07
Exercise price	\$0.04 to \$35.0	\$0.04 to \$35.0
Expiry date	Nov 2026 – Jul 2027	Nov 2026
Expected future volatility	135%	135%
Risk free rate	4.06%	4.06%
Dividend yield	Nil	Nil

For personal use only

**NOTE 7. CONTRIBUTED EQUITY**

	31-Dec-25 NUMBER	30-Jun-25 NUMBER	31-Dec-25 A\$	30-Jun-25 A\$
Ordinary Shares on issue, fully paid	83,384,867	72,183,153	139,618,424	138,587,034
	<b>83,384,867</b>	<b>72,183,153</b>	<b>139,618,424</b>	<b>138,587,034</b>

**Reconciliation of movement in share capital**

	No. Of Shares	Issue Price	Amount
<b>Opening balance at 01 July 2025</b>	<b>72,183,153</b>		<b>138,587,034</b>
Conversion of Mercer Convertible Notes - 4 Sep 2025	3,333,333	0.12	400,000
Issue of Shares to Creditors- 12 Sep 2025	2,252,381	0.10	235,000
Issue of Shares to employees - 12 Dec 2025	5,000,000	0.07	345,000
Issue of Shares to Creditors- 12 Dec 2025	616,000	0.10	61,600
Less: Costs of issue			(10,210)
<b>Closing balance at 31 December 2025</b>	<b>83,384,867</b>		<b>139,618,424</b>

**NOTE 8. SHARE BASED PAYMENTS**

A summary of number of performance rights and options on issue during the period are as below.

**Reconciliation of Performance Rights**

Opening Balance	Granted as compensation	Exercised	Lapsed	Outstanding at 31 December 2025
600,000	-	-	-	600,000

**Reconciliation of Options**

Opening Balance	Issued during the period	Exercised	Lapsed	Outstanding at 31 December 2025
44,194,775	22,032,952	-	-	66,227,727

**NOTE 9. LEASES**

Below are the carrying amounts of right-of-use assets recognised for the period:

	31-Dec-25 A\$	30-Jun-25 A\$
<b>Right-of-use assets</b>		
Opening balance	358,976	1,058,673
Depreciation	(121,315)	(226,548)
Decrease due to early termination of lease	-	(547,823)
Decrease due to liquidation of subsidiary (Note 12)	(177,215)	-
Foreign exchange	(4,589)	74,674
<b>Closing balance</b>	<b>55,857</b>	<b>358,976</b>

Below are the carrying amounts of lease liabilities for the period:

	31-Dec-25 A\$	30-Jun-25 A\$
<b>Lease liabilities</b>		
Opening balance	357,727	1,044,724
Interest	15,483	38,518
Lease payments	(123,446)	(239,255)
Decrease on early termination of lease	-	(560,158)
Decrease due to liquidation of subsidiary (Note 12)	(175,290)	-
Foreign exchange	(4,721)	73,898
<b>Closing balance</b>	<b>69,753</b>	<b>357,727</b>
Current	14,502	109,182
Non-current	55,251	248,545
<b>Total lease liability</b>	<b>69,753</b>	<b>357,727</b>

#### NOTE 10. ADMINISTRATIVE EXPENSES

	31-Dec-25 A\$	31-Dec-24 A\$
<b>Administrative expenses</b>		
Corporate costs	85,541	179,949
Professional and consultancy fees	608,870	1,994,286
Board fees	457,073	241,335
Staff costs	337,203	1,359,278
Employee shares and share based payment expense	351,537	2,274,515
IR/PR Expenses	433,453	843,400
Advertising and Marketing	1,259	22,229
Depreciation	36,687	493,343
Other administration expense	204,569	254,812
<b>Total for period</b>	<b>2,516,192</b>	<b>7,663,147</b>

#### NOTE 11. RELATED PARTY TRANSACTIONS

There have been no material changes to related parties since 30 June 2025.

#### NOTE 12. LIQUIDATION OF SUBSIDIARY

In December 2025, Argent BioPharma d.o.o. was liquidated following the Company's strategic decision to cease operations at its manufacturing facility in Slovenia. As a result, the Group lost control of the subsidiary and derecognised its assets and liabilities. The liquidation resulted in a loss of A\$55,395, which has been recognised in the consolidated statement of profit or loss for the half-year ended 31 December 2025. The carrying amounts of the assets and liabilities derecognised at the date of liquidation were as follows:

	31-Dec-25 A\$
Total assets	774,962
Total liabilities	(1,334,037)
Foreign currency translation reserve	614,470
<b>Loss on liquidation</b>	<b>55,395</b>

**NOTE 13. EVENTS SUBSEQUENT TO REPORTING DATE**

On 14 January 2026, the Company signed the binding agreement to streamline strategic acquisition of AusCann assets to advance CannEpiL.

On 15 January 2026, the Company issued 1,000,000 ordinary shares upon the conversion of 56,400 Convertible Notes at a conversion price of A\$0.0564.

On 10 February 2026, the Company issued 2,557,450 ordinary shares issued as consideration for purchase order reimbursement.

Other than those matters disclosed in the interim financial statements, there have been no significant events occurring after the balance date which may affect either the Group's operations or results of those operations or the group's state of affairs.

**NOTE 14. SEGMENT REPORTING**

Geographic information on the Group's revenue by location of operations for the period and non-current assets at 31 December 2025 is as follows:

	Malta A\$	Slovenia A\$	Australia and others A\$	Total A\$
<b>31-Dec-25</b>				
Sales revenue	-	171,499	-	<b>171,499</b>
Total assets	187,656	46,260	1,776,656	<b>2,010,572</b>
<b>30-Jun-25</b>				
Sales revenue	-	180,565	-	<b>180,565</b>
Total assets	187,656	1,048,387	1,231,635	<b>2,467,678</b>

## Directors' Declaration

The Directors of the Company declare that:

1. the interim financial statements and notes, are in accordance with the *Corporations Act 2001* and:
  - a) comply with Australian Accounting Standard AASB134 Interim financial reporting and the Corporations Regulations 2001; and
  - b) give a true and fair view of the Group's financial position as at 31 December 2025 and its performance for the half year ended on that date; and
2. Subject to the matters set out in note 2, there are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors, pursuant to s 303(5) of the Corporations Act.



Roby Zomer  
Managing Director & CEO  
Dated 27 February 2026

For personal use only

ARGENT BIOPHARMA LTD  
ABN 30 116 800 269  
AND ITS CONTROLLED ENTITIES

INDEPENDENT AUDITOR'S REVIEW REPORT  
TO THE MEMBERS OF ARGENT BIOPHARMALTD

## Conclusion

We have reviewed the half-year financial report of Argent Biopharma Ltd (the company) and its controlled entities (the group), which comprises the consolidated statement of financial position as at 31 December 2025, the consolidated statement of profit and loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year then ended, a summary of material accounting policies and other explanatory information, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of the group does not comply with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the group's financial position as at 31 December 2025 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134: *Interim Financial Reporting and the Corporations Regulations 2001*.

## Basis for Conclusion

We conducted our review in accordance with ASRE 2410: *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Financial Report* section of our report. We are independent of the group in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110: *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

## Material Uncertainty Related to Going Concern

We draw attention to Note 2 in the financial report, which indicates that the group incurred a net loss of \$2,935,261 during the half-year ended 31 December 2025 and, as of that date, the group's current liabilities exceeded its current assets by \$7,196,742. As stated in Note 2, these events or conditions, along with other matters as set forth in Note 2, indicate that a material uncertainty exists that may cast significant doubt on the group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

## Responsibility of the Directors for the Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

<p><b>ADELAIDE</b> Level 9 50 Pirie Street Adelaide SA 5000 T: +61 8 7093 8283</p>	<p><b>BRISBANE</b> Level 19 240 Queen Street Brisbane QLD 4000 T: +61 7 2111 7000</p>	<p><b>DARWIN</b> Level 1 48-50 Smith Street Darwin NT 0800 T: +61 8 8943 0645</p>	<p><b>MELBOURNE</b> Level 14 440 Collins Street Melbourne VIC 3000 T: +61 3 9820 6400</p>	<p><b>PERTH</b> Level 11 77 St Georges Tce Perth WA 6000 T: +61 8 6557 6200</p>	<p><b>SYDNEY</b> Level 40 2 Park Street Sydney NSW 2000 T: +61 2 9263 2600</p>
--	---	---	---	---	--

[www.hallchadwick.com.au](http://www.hallchadwick.com.au)

Liability limited by a scheme approved under Professional Standards Legislation. Hall Chadwick (NSW) Pty Ltd ABN: 32 103 221 352

ARGENT BIOPHARMA LTD  
ABN 30 116 800 269  
AND ITS CONTROLLED ENTITIES

INDEPENDENT AUDITOR'S REVIEW REPORT  
TO THE MEMBERS OF ARGENT BIOPHARMALTD

*Auditor's Responsibility for the Review of the Financial Report*

ASRE 2410 requires us to conclude whether we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the group's financial position as at 31 December 2025 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134: *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



HALL CHADWICK (NSW)  
Level 40, 2 Park Street  
Sydney NSW 2000



**ANTHONY TRAVERS**

Partner

Dated: 27 February 2026